ReviewProstaglandins & other lipid mediators2018
Mechanisms of isolevuglandin-protein adduct formation in inflammation and hypertension.
Review in Prostaglandins & other lipid mediators, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Beyond Blood Pressure: Salt Sensitivity as a Cardiorenal Phenotype-A Narrative Review.Life (Basel, Switzerland) · 2026Review
- Innate immunity and hypertension: unveiling inflammatory pathways for novel therapies.Frontiers in pharmacology · 2026Review
- Integrated mechanisms linking sodium-potassium imbalance to salt-sensitive hypertension.Physiological reports · 2025Review
- Aging and sex differences in salt sensitivity of blood pressure.Clinical science (London, England : 1979) · 2025Review
- Innovative assessment of lipid-induced oxidative stress and inflammation in harvested human endothelial cells.Physiological reports · 2024Article
- High salt intake and HIV infection on endothelial glycocalyx shedding in salt-sensitive hypertension.Frontiers in cell and developmental biology · 2024Review
- The Antioxidative Effects of Flavones in Hypertensive Disease.Biomedicines · 2023Review
- Glycocalyx-Sodium Interaction in Vascular Endothelium.Nutrients · 2023Review
- Hypertensive heart disease: risk factors, complications and mechanisms.Frontiers in cardiovascular medicine · 2023Review
- Gut microbiota dependant trimethylamine N-oxide and hypertension.Frontiers in physiology · 2023Review
- Rosetta FlexPepDock to predict peptide-MHC binding: An approach for non-canonical amino acids.PloS one · 2022Article
- Neutrophil gelatinase-associated lipocalin as an immunomodulator in endocrine hypertension.Frontiers in endocrinology · 2022Review
- Isolevuglandin-Modified Cardiac Proteins Drive CD4+ T-Cell Activation in the Heart and Promote Cardiac Dysfunction.Circulation · 2021Article
- Mass Spectrometry-Based Methodologies for Targeted and Untargeted Identification of Protein Covalent Adducts (Adductomics): Current Status and Challenges.High-throughput · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Inflammation has been implicated in the pathogenesis of hypertension and recent evidence suggests that isolevuglandin (IsoLG)-protein adducts play a role. Several hypertensive stimuli contribute to formation of IsoLG-protein adducts including excess dietary salt and catecholamines. The precise intracellular mechanisms by which these hypertensive stimuli lead to IsoLG-protein adduct formation are still not well understood; however, there is now evidence implicating NADPH-oxidase derived reactive oxygen species (ROS) in this process. ROS oxidize arachidonic acid leading to formation of IsoLGs, which non-covalently adduct to lysine residues and alter protein structure and function. Recent studies suggest that these altered proteins act as neo-antigens leading to an autoimmune state that results in hypertension. The goal of this mini-review is to highlight some of the hypertensive stimuli and the mechanisms contributing to IsoLG-protein adduct formation leading to inflammation and hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.